They evaluated the efficacy of MEK162 in patients with advanced melanoma with NRAS or Val600 BRAF mutations. Median follow-up was 3.3 months (range 0.6-8.7; IQR 2.2-5.0). No patient had a CR. Six (20%) of 30 patients with NRAS-mutant melanoma had a PR (3 confirmed) and 8 (20%) of 41 patients with BRAF-mutated melanoma had a PR (2 confirmed). Rash occurred in 6 (20%) patients with NRAS-mutant melanoma and 16 (39%) patients with BRAF-mutant melanoma. There were no deaths from treatment-related causes. Here, NRAS is linked to melanoma.